Ignite Creation Date:
2025-12-25 @ 12:30 AM
Ignite Modification Date:
2025-12-25 @ 10:37 PM
Study NCT ID:
NCT07116967
Status:
RECRUITING
Last Update Posted:
2025-12-23
First Post:
2025-08-04
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
Sponsor:
Bristol-Myers Squibb
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2025-09-22
Start Date Type:
ACTUAL
Primary Completion Date:
2031-01-16
Primary Completion Date Type:
ESTIMATED
Completion Date:
2031-01-16
Completion Date Type:
ESTIMATED
First Submit Date:
2025-08-04
First Submit QC Date:
None
Study First Post Date:
2025-08-12
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-12-22
Last Update Post Date:
2025-12-23
Last Update Post Date Type:
ESTIMATED